LLY-283 is primarily utilized in research settings as a potent and selective inhibitor of the enzyme PRMT5 (Protein Arginine Methyltransferase 5). It is employed to study the role of PRMT5 in various cellular processes, including gene expression, RNA splicing, and cell proliferation. Researchers use LLY-283 to investigate its potential therapeutic effects in diseases where PRMT5 is dysregulated, such as certain cancers. By inhibiting PRMT5, LLY-283 helps in understanding the enzyme's function and its impact on tumor growth and survival, aiding in the development of targeted cancer therapies. Additionally, it serves as a valuable tool in preclinical studies to explore the biological pathways influenced by PRMT5 and to assess the efficacy of PRMT5 inhibition in disease models.